SEC 13F Intelligence

Managers / Q1 2026

Exome Asset Management LLC

CIK 0002011932 · 330 MADISON AVENUE, NEW YORK, NY, 10017 · 212-403-3900

Reported Value
$193M
Q1 2026
Positions
56
Filings on Record
14
2019–present window
Filed
May 15, 2026
original filing

Summary

Exome Asset Management LLC reported $193M in U.S.-listed holdings across 56 positions for Q1 2026.

Its largest position, PRAX, represents 7.6% of the portfolio.

Compared with Q4 2025, the fund opened 22 new positions and exited 27.

Portfolio Metrics

Turnover
+36.2%
vs prior filed quarter
Top-10 Concentration
+40.8%
share of reported value
Largest Position
+7.6%
Praxis Precision Medicines I
New / Exited
22 / 27
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’23: $101MQ4 ’23Q1 ’24: $117MQ2 ’24: $115MQ2 ’24Q3 ’24: $146MQ4 ’24: $133MQ4 ’24Q1 ’25: $112MQ2 ’25: $135MQ2 ’25Q3 ’25: $165MQ4 ’25: $209MQ4 ’25Q1 ’26: $193Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 82.3%Other: 11.5%ETP: 4.0%ADR: 2.2%
  • Common Stock · 82.3% · $159M
  • Other · 11.5% · $22M
  • ETP · 4.0% · $8M
  • ADR · 2.2% · $4M

Quarter-over-Quarter Changes full breakdown →

vs Q4 2025 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
SPDR SERIES TRUSTNEW+60.0K60.0K+$8M$8M
IM8NINSMED INCNEW+26.7K26.7K+$4M$4M
MLTXMOONLAKE IMMUNOTHERAPEUTICSNEW+215.4K215.4K+$4M$4M
CYTOKINETICS INCNEW+60.0K60.0K+$4M$4M
RYTMRHYTHM PHARMACEUTICALS INCNEW+40.6K40.6K+$4M$4M
BSXBOSTON SCIENTIFIC CORPNEW+48.3K48.3K+$3M$3M
ALKERMES PLCNEW+84.1K84.1K+$3M$3M
BEONE MEDICINES LTDNEW+10.0K10.0K+$3M$3M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2026

42 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1PRAXPRAXIS PRECISION MEDICINES Ihistory →COM NEW7.58%$15M45.5K
2COGTCOGENT BIOSCIENCES INChistory →COM5.54%$11M278.5K
3ELVNENLIVEN THERAPEUTICS INChistory →COM4.46%$9M220.1K
4ISIIONIS PHARMACEUTICALS INChistory →COM4.27%$8M110.1K
5GHGUARDANT HEALTH INChistory →COM3.95%$8M82.7K
6CYTKCYTOKINETICS INChistory →COM NEW3.54%$7M103.7K
7LLYELI LILLY & COhistory →COM3.34%$6M7.0K
8ALMSALUMIS INChistory →COM3.18%$6M279.2K
9BBIOBRIDGEBIO PHARMA INChistory →COM2.59%$5M67.5K
10VERAVERA THERAPEUTICS INChistory →CL A2.39%$5M115.0K
11IM8NINSMED INChistory →COM PAR $.012.25%$4M26.7K
12ELVELEVANCE HEALTH INC FORMERLYhistory →COM2.22%$4M14.7K
13AGIOAGIOS PHARMACEUTICALS INChistory →COM2.19%$4M125.1K
14UTHUNITED THERAPEUTICS CORP DELhistory →COM2.16%$4M7.1K
15MLTXMOONLAKE IMMUNOTHERAPEUTICShistory →CLASS A ORD2.08%$4M215.4K
16NTRANATERA INChistory →COM1.93%$4M18.6K
17RYTMRHYTHM PHARMACEUTICALS INChistory →COM1.83%$4M40.6K
18UNHUNITEDHEALTH GROUP INChistory →COM1.80%$3M12.9K
19APLSUSDAPELLIS PHARMACEUTICALS INChistory →COM1.78%$3M85.5K
20VSTMVERASTEM INChistory →COM NEW1.75%$3M636.7K
21TXG10X GENOMICS INChistory →CL A COM1.69%$3M154.2K
22BSXBOSTON SCIENTIFIC CORPhistory →COM1.57%$3M48.3K
23ALKERMES PLCSHS1.54%$3M84.1K
24GLUEMONTE ROSA THERAPEUTICS INChistory →COM1.53%$3M179.5K
25ISRGINTUITIVE SURGICAL INChistory →COM NEW1.52%$3M6.4K
26ADAGADAGENE INChistory →ADS1.49%$3M736.8K
27ARWRARROWHEAD PHARMACEUTICALS INhistory →COM1.48%$3M45.7K
28CRESCENT BIOPHARMA INC.COM1.46%$3M153.2K
29RLAYRELAY THERAPEUTICS INChistory →COM1.43%$3M278.3K
30MAZEMAZE THERAPEUTICS INChistory →COM1.37%$3M88.5K
31CTMXCYTOMX THERAPEUTICS INC.history →COM1.27%$2M521.5K
32AVTXAVALO THERAPEUTICS INChistory →COM NEW1.23%$2M159.3K
33GKOSGLAUKOS CORPhistory →COM1.16%$2M20.9K
34CRBPCORBUS PHARMACEUTICALS HLDGShistory →COM NEW1.14%$2M234.1K
35PENPENUMBRA INChistory →COM1.07%$2M6.3K
36SLNOEURSOLENO THERAPEUTICS INChistory →COM1.07%$2M61.7K
37LQDALIQUIDIA CORPORATIONCOM NEW0.89%$2M45.8K
38ZBIOZENAS BIOPHARMA INCCOM0.82%$2M80.7K
39NBPNOVABRIDGE BIOSCIENCESSPONSORED ADS0.73%$1M577.0K
40FDMT4D MOLECULAR THERAPEUTICS INCOM0.63%$1M130.6K
41NXTCNEXTCURE INCCOM NEW0.63%$1M115.5K
42PALIPALISADE BIO INCCOM0.54%$1M600.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$193M56May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$209M60Feb 13, 202613F-HRchanges · EDGAR ↗
Q3 2025$165M68Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$135M63Aug 15, 2025RESTATEMENTchanges · EDGAR ↗
Q1 2025$112M59May 16, 2025RESTATEMENTchanges · EDGAR ↗
Q4 2024$133M59Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$146M56Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$115M50Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$117M53May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$101M52Feb 15, 202413F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.